Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.…
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
Ardelyx (NASDAQ: ARDX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 489 employees.
The shares were at 2.990 USD on 20 November 2026, down 46.5% over 52 weeks. Its 52-week range is 2.800 USD to 8.400 USD: the price is 64.4% below the high and 6.8% above the low.
Its market capitalisation is 751.60M USD.
Ardelyx reports return on equity of -36.9%, an operating margin of -7.7% and revenue up 15.7% year over year.
It holds more cash than debt, a net cash position of 1.78M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 18 February 2027.